AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option
AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data on Friday from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under which Pfizer Inc. (NYSE:PFE) may buy out AM-Pharma.
On the 301-patient...
Read the full 207 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$50 USD
